Estimation From Censored Medical Cost Baser Onur Outcomes Research and Econometrics, Medstat Bradley Cathy Department of Medicine, Michigan State University Gardiner Joseph Department of Statistics, Michigan State University Given Bill Department of Family Practice, Michigan State University IHEA, 2003

Copyright 2003 Thomson Medstat2 Overview Medstat support throughout product life cycle Medstat overview MarketScan ® Research Databases Understanding the marketplace Clinical trial services –Recruitment –Economic protocol design –Health economic analysis Pharmaceutical research capabilities –Retrospective studies –Prospective studies

Copyright 2003 Thomson Medstat3 Medstat Support Throughout Product Life Cycle Phase I –Assessment of current marketplace, market potential for therapeutic areas Phase II, Early Phase III –Tools for faster, more efficient clinical trial recruitment –Health economic analyses in Phase II before bigger gamble of Phase III trial –Economic protocol development for clinical trials, designed to capture compelling economic endpoints Late Phase III, Phase IV –Data assets that reflect the real world of healthcare delivery and include measures of medical care and worker productivity –Budget impact models –Retrospective studies of burden of illness, cost effectiveness, and health outcomes –Prospective studies

Copyright 2003 Thomson Medstat4 Medstat A healthcare information company that: –Serves all major market segments –Is differentiated by product leadership and innovation –Holds longest track record in industry (founded 1981) –Employs approximately 700 employees in nine locations –Is part of The Thomson Corporation

Copyright 2003 Thomson Medstat5 Principal Product Lines Decision support software and consulting services –Large data warehouses –Clinically relevant software and methodologies Information assets –MarketScan –PULSE™ Survey Research –Custom data build capabilities –Retrospective, prospective, and survey studies –Disease management and program evaluations